PC

Punjab Chemicals

Q1 FY27Fertilizers & Agrochemicals

Punjab Chemicals Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price1,093
Market cap₹1.4K Cr
P/E21.0
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 3
MarginRank 1
CapexYes
Order bookYes

Not discussed on this call: fundraise.

The short version

Targeted revenue growth of 15%-20% for FY27, with a stronger H2 expected than H1. Management targets revenue growth of 15%-20% for FY27, especially stronger in H2, driven by a mix of agrochemical and pharmaceutical intermediates (Page 10).

From Punjab Chemicals's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3
  • Targeted revenue growth of 15%-20% for FY27, with a stronger H2 expected than H1.
  • Q1 saw 8.7% year-on-year revenue growth; exports grew 27.7% while domestic declined marginally by 3.1%.
  • New products are expected to contribute 15%-18% of revenue in FY27, growing over time towards 20%+.
  • Increased focus on new product commercialization—4 to 5 products expected to launch yearly, with some adding INR40-50 crores each over 3-4 years.
  • Expansion in capacity (e.g., new manufacturing block at Lalru and pilot plant revamp) to support growth.
  • Growing CDMO business with advanced discussions expected to add 2-3 new customers on multi-year contracts.
  • Strong order book visibility for Q2 to Q4 supports medium-term growth confidence.
  • Agrochemicals to remain dominant segment (65%-70%) with balanced CDMO and catalog product mix around 50:50.

Profitability & Margins

See what Punjab Chemicals said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • Greenfield capex is planned to start in FY27 as a clear goal for long-term growth across agro and specialty chemicals.
  • New manufacturing block at the Lalru plant is under construction; civil work has commenced, with major investment in Q2 and Q3 FY27.
  • A revamp of the pilot plant is underway, targeting completion by September-October 2026, to increase capacity for simultaneous scale-up of multiple products.
  • Expansion of R&D facilities has doubled in size over the last 2 years, enhancing product scale-up and development pipeline.
  • Continuous addition of 4-5 new products annually to commercial portfolio, supported by investments in capacity and R&D infrastructure.
  • Evaluation ongoing for a new manufacturing site to support incremental growth and product pipeline beyond current facilities.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential
2Dharmaj Crop
Rev 2Mar 2
3
Rev 2Mar 3
4
Rev 3Mar 3
5
Rev 3Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Punjab Chemicals said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes
  • The order book for the year provides reasonable visibility on existing businesses.
  • For Q1, Q2, and part of Q3, there is clear visibility of achieving volumes as per original predictions.
  • Management mentioned a strong order position moving forward for Q2 and Q3.
  • While a precise breakup between new products and legacy products in the order book wasn't provided, new products are targeted to contribute 15% to 18% of revenue in FY27.
  • Several commercial lot supplies have been made for MoU products, with volume ramp-up expected from Q4 FY27.
  • The company continues to engage with customers for long-term contracts, especially in Europe, Japan, and domestic markets, indicating ongoing and growing order interest.
  • Expansion in R&D and infrastructure aims to support increasing demand and order fulfillment.

Punjab Chemicals — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹209 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Fertilizers & Agrochemicals this season

  • Indogulf Cropsci (Q1 FY27)

    1800+ crores within 2-3 years. Key concall takeaways from Indogulf Cropsciences Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

  • G S F C (Q1 FY27)

    Profit after tax increased by 15% YoY in Q1 FY27, signaling positive growth trajectory. Key concall takeaways from Gujarat State Fertilizers & Chemicals Ltd's…

  • GSP Crop Science (Q1 FY27)

    Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…

  • Rallis India Ltd (Q1 FY27)

    . Key concall takeaways from Rallis India's Q1 FY27 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Punjab Chemicals Q1 FY27 results?

Targeted revenue growth of 15%-20% for FY27, with a stronger H2 expected than H1. Management targets revenue growth of 15%-20% for FY27, especially stronger in H2, driven by a mix of agrochemical and pharmaceutical intermediates (Page 10).

What is Punjab Chemicals share price analysis?

Punjab Chemicals currently shows a below-average growth signal. The stock trades at a P/E of 21.0 with a market cap of ₹1,407 Cr. Investors should review the full earnings analysis for detailed insights.

Is Punjab Chemicals planning capital expenditure?

Greenfield capex is planned to start in FY27 as a clear goal for long-term growth across agro and specialty chemicals.

Keep Punjab Chemicals on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.